- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.09. | Journey Medical: Rosazea-Medikament Emrosi treibt Wachstum an | 1 | Investing.com Deutsch | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 13.08. | Journey Medical signals continued ASP gains in 2H 2026 as Emrosi reaches $8.1M and 38% high-quality coverage | 19 | Seeking Alpha | ||
| 12.08. | Journey Medical steigert Umsatz im zweiten Quartal 2026 und erreicht positives EBITDA | 1 | Investing.com Deutsch | ||
| 12.08. | Journey Medical übertrifft Prognosen für Q2 2026 - Aktie legt zu | 1 | Investing.com Deutsch | ||
| 12.08. | Journey Medical Non-GAAP EPS of $0.10, revenue of $18.5M beats by $0.13M | 2 | Seeking Alpha | ||
| 12.08. | Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights | 241 | GlobeNewswire (Europe) | Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi revenues were $8.1 million for the second quarter of 2026 Strong revenue... ► Artikel lesen | |
| 05.08. | Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026 | 1 | GlobeNewswire (USA) | ||
| 14.05. | Journey Medical signals positive EBITDA for remainder of 2026 as it plans to add up to 5 sales professionals | 3 | Seeking Alpha | ||
| 13.05. | Journey Medical: Starker Gewinn pro Aktie, aber Umsatz enttäuscht | 9 | Investing.com Deutsch | ||
| 13.05. | Transcript: Journey Medical Q1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 13.05. | Journey Medical: EPS übertrifft Schätzungen um 0,05 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 13.05. | Journey Medical Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 362 | GlobeNewswire (Europe) | Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased... ► Artikel lesen | |
| 06.05. | Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 | 2 | GlobeNewswire (USA) | ||
| 25.03. | Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | 454 | GlobeNewswire (Europe) | Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately... ► Artikel lesen | |
| 12.11.25 | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 394 | GlobeNewswire (Europe) | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 26,750 | +0,62 % | Community Rückblick: BioNTech BNT113 Studie verfehlt Endpunkt: "Die Bude treibt einen zum Wahnsinn!" | © Foto: Julia Cebella - dpaBioNTech verfehlt mit BNT113 ein wichtiges Studienziel. Im wO-Forum streiten Anleger über die Zukunft der mRNA-Krebsforschung, die Bewertung der Aktie und das Potenzial der... ► Artikel lesen | |
| GILEAD SCIENCES | 135,54 | -0,86 % | BofA hebt Kursziel für Gilead Sciences nach positiven Studiendaten an | ||
| ELI LILLY | 1.142,00 | +0,87 % | Eli Lilly kauft Psychedelika-Riesen: Warum Emyria jetzt die perfekte Ergänzung für den Milliarden-Markt baut | ||
| VERTEX PHARMACEUTICALS | 469,85 | +0,61 % | 115 Millionen US-Dollar mit einer Zelltherapie: Warum Mesoblast, Vertex und NurExone Zellen und Exosomen unterschiedlich nutzen | ||
| EYEPOINT | 0,380 | -1,04 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 35,220 | +3,28 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,587 | 0,00 % | FILANA THERAPEUTICS, INC. - 8-K, Current Report | ||
| LIGAND PHARMACEUTICALS | 260,00 | -7,14 % | Ligand Pharmaceuticals: Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026 | ||
| JAZZ PHARMACEUTICALS | 191,20 | +1,35 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026 | Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its... ► Artikel lesen | |
| UNITED THERAPEUTICS | 504,00 | +0,52 % | United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500? | ||
| OPKO HEALTH | 1,440 | +0,70 % | Labcorp To Acquire BioReference Health Assets; OPKO Shares Rise 7.35% | WASHINGTON (dpa-AFX) - Labcorp Holdings Inc. (LH), a provider of innovative and comprehensive laboratory services, on Thursday announced that it had agreed to acquire select assets of BioReference... ► Artikel lesen | |
| ROYALTY PHARMA | 55,37 | +0,07 % | Royalty Pharma declares $0.235 dividend | ||
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 60,63 | +0,53 % | BridgeBio Pharma (NDQ:BBIO): 5 Years From A Near-Death Experience, Its Has A Cumulative Opportunity Of ~$30bn At Its Fingertips! | ||
| TG THERAPEUTICS | 46,400 | 0,00 % | TG Therapeutics, Inc.: TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia | NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant... ► Artikel lesen |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 4,795 Euro und damit -0,10 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.